Orphanet: Simple search

Search for a clinical trial

Other search option(s)

185 Result(s)

National clinical trial(s)

MAINTAIN: Prospective randomized Multicenter study in first-line treatment of Advanced progredIeNT follicular And other IndoleNt and mantle cell lymphomas (phase III) - AT Kepler Universitätsklinikum - Med Campus III. Klinik für Interne 3 - Schwerpunkt Hämatologie und Onkologie

MAINTAIN: Prospective randomized Multicenter study in first-line treatment of Advanced progredIeNT follicular And other IndoleNt and mantle cell lymphomas (phase III) - AT Medizinische Universität Innsbruck Universitätsklinik für Innere Medizin V - Hämatologie und Onkologie

CHRONOS-3: A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - AT Institution: Information not provided - AT

MAINTAIN: Prospective randomized Multicenter study in first-line treatment of Advanced progredIeNT follicular And other IndoleNt and mantle cell lymphomas (phase III) - AT Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Hämatologie und Hämostaseologie

An Open-label, Phase 1b/2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia - AT Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Hämatologie und Hämostaseologie

LYMRIT-37-01: A Phase I/II Study of 177Lu-HH1 (Betalutin®) Radioimmunotherapy for Treatment of Relapsed Non-Hodgkin Lymphoma - AT Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Onkologie

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - BE Institution: Information not provided - BE

CHRONOS-3: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL)- BE CHU Brugmann Hémato-oncologie

A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents - FR Institution: Information not provided - FR

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas -FR Institution: Information not provided - FR

CHRONOS-3 : A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) - FR Institution: Information not provided - FR

VISMOLY : Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia CHU de Rennes - Hôpital Pontchaillou Service d'hématologie clinique

A phase IIa trial testing the efficacy of Bortezomib (Velcade) in patients with advanced Waldenström macroglobulinemia (WM2) CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière Service d'Hématologie clinique

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - FR CLCC Henri Becquerel Service d'Hématologie

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) -DE- Universitätsklinikum Freiburg

Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia -DE- Universitätsklinikum Ulm Institut für Experimentelle Tumorforschung

ECWM-2: Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström's Macroglobulinemia -DE- Universitätsklinikum Ulm Institut für Experimentelle Tumorforschung

CLL3X: Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplantation for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia (Phase II) - DE Universitätsklinikum Ulm am Oberen Eselsberg Klinik für Innere Medizin III

DELTA: A Phase 2 study to assess the efficacy and safety of CAL-101 in patients with indolent B-Cell Non-Hodgkin Lymphoma refractory to Rituximab and alkylating agents - DE LMU Klinikum der Universität München - Campus Großhadern Medizinische Klinik und Poliklinik III

NHL 7-2008 (MAINTAIN): Prospective randomized Multicenter study in first-line treatment of Advanced progredIeNT follicular And other Indolent and mantle cell lymphomas (Phase III) - DE Medizinische Klinik IV und V des UKGM am Standort Gießen Medizinische Klinik IV

GLSG Go-Study: Multicentric Phase I/II Study for the efficacy of a combination of Rituximab, Gemcitabine and Oxaliplatin in relapsed/refractory indolent Lymphoma - DE Klinikum der Stadt Ludwigshafen gGmbH Medizinische Klinik A

CHRONOS-3: A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - IE St James's Hospital Department of Haematology

Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia-GB St James's Hospital Department of Haematology

Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette S.C. di Ematologia

CHRONOS-3: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) - ES Hospital Universitario Virgen de la Victoria

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES Hospital Universitario Virgen del Rocío Unidad de Hematología

Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network - ES (terminated) Hospital Clínico Universitario de Salamanca Servicio de Hematología

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES Hospital Clínico Universitario de Salamanca Servicio de Hematología

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES Hospital Clínico Universitario de Salamanca Servicio de Hematología

Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia (Phase III) - ES Hospital Clínico Universitario de Salamanca Servicio de Hematología

An Open-label, Phase 1b/2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia - ES (terminated) Hospital Clínico Universitario de Salamanca Servicio de Hematología

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstrom´s Macroglobulinemia - ES (completed) ICO Badalona - Hospital Germans Trias i Pujol Servicio de Hematología Clínica

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES ICO Badalona - Hospital Germans Trias i Pujol Servicio de Hematología Clínica

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES Hospital Clínic de Barcelona Servicio de Hematología

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES Hospital Universitari Vall d'Hebron Servicio de Hematología y hemoterapia

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES Hospital Universitari Vall d'Hebron Servicio de Hematología y hemoterapia

CHRONOS-3: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) - ES Hospital de la Santa Creu i Sant Pau Servicio de Hematología

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES Hospital de la Santa Creu i Sant Pau Servicio de Hematología

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES Hospital de la Santa Creu i Sant Pau Servicio de Hematología

CHRONOS-3: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) - ES Hospital del Mar Servicio de Hematología

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES ICO Hospitalet - Hospital Duran i Reynals Servicio de Hematología Clínica

CHRONOS-1: Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin's lymphomas - ES Hospital Universitario y Politécnico La Fe Servicio de Oncología Médica

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES Hospital Universitario da Coruña Unidad de Hematología Clínica

CHRONOS-3: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) - ES Hospital Universitario 12 de Octubre

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES Hospital Universitario Puerta de Hierro - Majadahonda Servicio de Hematología y Hemoterapia

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES Clínica Universidad de Navarra Servicio de Hematología y Hemoterapia

R2W: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for initial therapy of Waldenström macroglobulinaemia: a randomised phase II study St Bartholomew's Hospital, Barts and The London NHS Trust Haematological Oncology

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) -GB Institution: Information not provided - US

CHRONOS-2: A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - AT Institution: Information not provided - AT

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma - BE Institution: Information not provided - BE

GADOLIN: An open label, multicenter, randomized, phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + GADOLIN RO5072759 (GA101) in patients with rituximab-refractory, indolent non-Hodgkin's lymphoma - FR Institution: Information not provided - FR

A Phase I dose-escalation study of IPH2102, a fully human anti-KIR monoclonal antibody (CHO manufacturing), in patients with various hematologic or solid malignancies - FR Institution: Information not provided - FR

CHRONOS-2: A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - FR Institution: Information not provided - FR

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's Lymphoma - FR CLCC Institut Gustave Roussy Département d'hématologie

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) - DE Institution: Information not provided - DE

CHRONOS-4: A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL) - IE Bayer AG

Ofatumumab-Bendamustine For Relapsed-Refractory Indolent Lymphoma: A Multicenter Phase 2 Trial IRCCS Istituto Clinico Humanitas U.O. Oncologia Medica ed Ematologia

DYNAMO: A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma - ES (Completed) Hospital Universitario y Politécnico La Fe Servicio de Oncología Médica

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin?s Lymphoma - ES (completed) Institution: Information not provided - ES

NCRN538: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for previously Treated Indolent Non-Hodgkin Lymphomas - UK St Bartholomew's Hospital, Barts and The London NHS Trust Haematological Oncology

NCRN539: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas - UK Southampton General Hospital Cancer Sciences Division

IPI-145-06 - A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO) - UK University Hospital of Wales Department of Haematology

A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation - US Cleveland Clinic

SELINDA: A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP - BE Institut Jules Bordet Service d'hématologie

BIBLOS (BTK Inhibition in B-cell LymphOmaS): A Phase Ib Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas - BE CHU Sart Tilman - Liège Department of Hematology / Hématologie clinique

An open-label, phase 1 study of R-CVP or R-GDP in combination with Inotuzumab Ozogamicin in subjects with CD22-positive non-Hodgkin's lymphoma - FR Institution: Information not provided - FR

ROMULUS: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) - FR Institution: Information not provided - FR

A Phase Ib Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas - FR CHU de Lyon HCL - GH Sud Service d'hématologie clinique

A Phase 1 Study Of Pf-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-hodgkin's Lymphoma (Nhl) - FR CHU de Rennes - Hôpital Pontchaillou Service d'hématologie clinique

RAD001-R : A Phase I/II Study Investigating the Combination of RAD001 and Rituximab in Patients With Non-Hodgkin's Lymphomas CLCC Institut Gustave Roussy Département d'hématologie

A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies - DE Universitätsklinikum Köln Klinik I für Innere Medizin

A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies Universitätsklinikum Münster Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie

An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma (Phase II) - ES (completed) Institution: Information not provided - ES

A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies - ES Hospital Universitario 12 de Octubre Unidad de Ensayos Clínicos de Fase Temprana en Hematología

A Phase 1b-2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) - GB Institution: Information not provided - UK

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies - GB Institution: Information not provided - UK

MAINTAIN: Prospective randomized Multicenter study in first-line treatment of Advanced progredIeNT follicular And other IndoleNt and mantle cell lymphomas (phase III) - AT
Kepler Universitätsklinikum - Med Campus III.

Klinik für Interne 3 - Schwerpunkt Hämatologie und Onkologie

MAINTAIN: Prospective randomized Multicenter study in first-line treatment of Advanced progredIeNT follicular And other IndoleNt and mantle cell lymphomas (phase III) - AT
Medizinische Universität Innsbruck

Universitätsklinik für Innere Medizin V - Hämatologie und Onkologie

CHRONOS-3: A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - AT
Institution: Information not provided - AT

MAINTAIN: Prospective randomized Multicenter study in first-line treatment of Advanced progredIeNT follicular And other IndoleNt and mantle cell lymphomas (phase III) - AT
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Hämatologie und Hämostaseologie

An Open-label, Phase 1b/2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia - AT
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Hämatologie und Hämostaseologie

LYMRIT-37-01: A Phase I/II Study of 177Lu-HH1 (Betalutin®) Radioimmunotherapy for Treatment of Relapsed Non-Hodgkin Lymphoma - AT
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Onkologie

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - BE
Institution: Information not provided - BE

CHRONOS-3: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL)- BE
CHU Brugmann

Hémato-oncologie

A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents - FR
Institution: Information not provided - FR

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas -FR
Institution: Information not provided - FR

CHRONOS-3 : A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) - FR
Institution: Information not provided - FR

VISMOLY : Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
CHU de Rennes - Hôpital Pontchaillou

Service d'hématologie clinique

A phase IIa trial testing the efficacy of Bortezomib (Velcade) in patients with advanced Waldenström macroglobulinemia (WM2)
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière

Service d'Hématologie clinique

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - FR
CLCC Henri Becquerel

Service d'Hématologie

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) -DE-
Universitätsklinikum Freiburg

Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia -DE-
Universitätsklinikum Ulm

Institut für Experimentelle Tumorforschung

ECWM-2: Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström's Macroglobulinemia -DE-
Universitätsklinikum Ulm

Institut für Experimentelle Tumorforschung

CLL3X: Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplantation for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia (Phase II) - DE
Universitätsklinikum Ulm am Oberen Eselsberg

Klinik für Innere Medizin III

DELTA: A Phase 2 study to assess the efficacy and safety of CAL-101 in patients with indolent B-Cell Non-Hodgkin Lymphoma refractory to Rituximab and alkylating agents - DE
LMU Klinikum der Universität München - Campus Großhadern

Medizinische Klinik und Poliklinik III

NHL 7-2008 (MAINTAIN): Prospective randomized Multicenter study in first-line treatment of Advanced progredIeNT follicular And other Indolent and mantle cell lymphomas (Phase III) - DE
Medizinische Klinik IV und V des UKGM am Standort Gießen

Medizinische Klinik IV

GLSG Go-Study: Multicentric Phase I/II Study for the efficacy of a combination of Rituximab, Gemcitabine and Oxaliplatin in relapsed/refractory indolent Lymphoma - DE
Klinikum der Stadt Ludwigshafen gGmbH

Medizinische Klinik A

CHRONOS-3: A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - IE
St James's Hospital

Department of Haematology

Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia-GB
St James's Hospital

Department of Haematology

Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette

S.C. di Ematologia

CHRONOS-3: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) - ES
Hospital Universitario Virgen de la Victoria

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES
Hospital Universitario Virgen del Rocío

Unidad de Hematología

Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network - ES (terminated)
Hospital Clínico Universitario de Salamanca

Servicio de Hematología

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES
Hospital Clínico Universitario de Salamanca

Servicio de Hematología

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES
Hospital Clínico Universitario de Salamanca

Servicio de Hematología

Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia (Phase III) - ES
Hospital Clínico Universitario de Salamanca

Servicio de Hematología

An Open-label, Phase 1b/2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia - ES (terminated)
Hospital Clínico Universitario de Salamanca

Servicio de Hematología

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstrom´s Macroglobulinemia - ES (completed)
ICO Badalona - Hospital Germans Trias i Pujol

Servicio de Hematología Clínica

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES
ICO Badalona - Hospital Germans Trias i Pujol

Servicio de Hematología Clínica

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES
Hospital Clínic de Barcelona

Servicio de Hematología

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES
Hospital Universitari Vall d'Hebron

Servicio de Hematología y hemoterapia

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES
Hospital Universitari Vall d'Hebron

Servicio de Hematología y hemoterapia

CHRONOS-3: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) - ES
Hospital de la Santa Creu i Sant Pau

Servicio de Hematología

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES
Hospital de la Santa Creu i Sant Pau

Servicio de Hematología

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES
Hospital de la Santa Creu i Sant Pau

Servicio de Hematología

CHRONOS-3: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) - ES
Hospital del Mar

Servicio de Hematología

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES
ICO Hospitalet - Hospital Duran i Reynals

Servicio de Hematología Clínica

CHRONOS-1: Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin's lymphomas - ES
Hospital Universitario y Politécnico La Fe

Servicio de Oncología Médica

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES
Hospital Universitario da Coruña

Unidad de Hematología Clínica

CHRONOS-3: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) - ES
Hospital Universitario 12 de Octubre

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES
Hospital Universitario Puerta de Hierro - Majadahonda

Servicio de Hematología y Hemoterapia

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) - ES
Clínica Universidad de Navarra

Servicio de Hematología y Hemoterapia

R2W: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for initial therapy of Waldenström macroglobulinaemia: a randomised phase II study
St Bartholomew's Hospital, Barts and The London NHS Trust

Haematological Oncology

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM) -GB
Institution: Information not provided - US

CHRONOS-2: A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - AT
Institution: Information not provided - AT

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma - BE
Institution: Information not provided - BE

GADOLIN: An open label, multicenter, randomized, phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + GADOLIN RO5072759 (GA101) in patients with rituximab-refractory, indolent non-Hodgkin's lymphoma - FR
Institution: Information not provided - FR

A Phase I dose-escalation study of IPH2102, a fully human anti-KIR monoclonal antibody (CHO manufacturing), in patients with various hematologic or solid malignancies - FR
Institution: Information not provided - FR

CHRONOS-2: A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - FR
Institution: Information not provided - FR

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's Lymphoma - FR
CLCC Institut Gustave Roussy

Département d'hématologie

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) - DE
Institution: Information not provided - DE

CHRONOS-4: A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL) - IE
Bayer AG

Ofatumumab-Bendamustine For Relapsed-Refractory Indolent Lymphoma: A Multicenter Phase 2 Trial
IRCCS Istituto Clinico Humanitas

U.O. Oncologia Medica ed Ematologia

DYNAMO: A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma - ES (Completed)
Hospital Universitario y Politécnico La Fe

Servicio de Oncología Médica

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin?s Lymphoma - ES (completed)
Institution: Information not provided - ES

NCRN538: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for previously Treated Indolent Non-Hodgkin Lymphomas - UK
St Bartholomew's Hospital, Barts and The London NHS Trust

Haematological Oncology

NCRN539: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas - UK
Southampton General Hospital

Cancer Sciences Division

IPI-145-06 - A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO) - UK
University Hospital of Wales

Department of Haematology

A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation - US
Cleveland Clinic

SELINDA: A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP - BE
Institut Jules Bordet

Service d'hématologie

BIBLOS (BTK Inhibition in B-cell LymphOmaS): A Phase Ib Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas - BE
CHU Sart Tilman - Liège

Department of Hematology / Hématologie clinique

An open-label, phase 1 study of R-CVP or R-GDP in combination with Inotuzumab Ozogamicin in subjects with CD22-positive non-Hodgkin's lymphoma - FR
Institution: Information not provided - FR

ROMULUS: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) - FR
Institution: Information not provided - FR

A Phase Ib Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas - FR
CHU de Lyon HCL - GH Sud

Service d'hématologie clinique

A Phase 1 Study Of Pf-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-hodgkin's Lymphoma (Nhl) - FR
CHU de Rennes - Hôpital Pontchaillou

Service d'hématologie clinique

RAD001-R : A Phase I/II Study Investigating the Combination of RAD001 and Rituximab in Patients With Non-Hodgkin's Lymphomas
CLCC Institut Gustave Roussy

Département d'hématologie

A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies - DE
Universitätsklinikum Köln

Klinik I für Innere Medizin

A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies
Universitätsklinikum Münster

Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie

An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma (Phase II) - ES (completed)
Institution: Information not provided - ES

A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies - ES
Hospital Universitario 12 de Octubre

Unidad de Ensayos Clínicos de Fase Temprana en Hematología

A Phase 1b-2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) - GB
Institution: Information not provided - UK

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies - GB
Institution: Information not provided - UK

A Cancer Research UK Phase I/IIa Clinical Trial of BI-1206; an Antibody to FcgRIIB (CD32b), as a Single Agent and in Combination With an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Malignancy
Southampton General Hospital

Cancer Sciences Division

Single Arm Phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) as non-toxic therapy against myeloid and lymphoid cancers - BaP
University of Birmingham

School of Cancer Sciences

An Open-label, Randomized, Phase 1 Study of R-CVP or R-GDP in Combination with Inotuzumab Ozogamicin in Subjects with CD22-Positive Non-Hodgkin's Lymphoma - UK
National Cancer Research Coordinating Centre

A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (Completed)
Seattle Genetics, Inc.